Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 5/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 4/20 | 0.39 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP7 | P09237 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29420340 | 0.82 | FFAR1 (0.44) | PDK2FFAR1FEN1ALOX5APACSS2 | |
| SCHEMBL16045671 | 0.81 | PDK2 (0.58) | PDK2FEN1 | |
| SCHEMBL21662459 | 0.79 | KCNH2 (0.49) | PDK2ALOX5APS1PR1MMP1MMP2 | |
| SCHEMBL31147921 | 0.75 | PDK2 (0.45) | PDK2S1PR1 | |
| SCHEMBL18183699 | 0.73 | AXL (0.50) | PDK2FEN1ALOX5AP | |
| SCHEMBL3852435 | 0.73 | ALOX5AP (0.37) | FFAR1FEN1ALOX5APMMP1MMP2 | |
| SCHEMBL23218013 | 0.72 | PDK2 (0.41) | PDK2FFAR1FEN1 | |
| SCHEMBL1953780 | 0.72 | MMP1 (0.43) | FFAR1FEN1ALOX5APMMP1MMP2 | |
| SCHEMBL3888920 | 0.71 | ALDH1A1 (0.46) | PDK2 | |
| SCHEMBL25433566 | 0.70 | L3MBTL1 (0.59) | PDK2S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002392-A1 | Imidazotriazines and Imidazopyrimidines as Kinase Inhibitors | INCYTE CORPORATION | 2023-01-05 | — | — | US | disclosed |
| US-11261191-B2 | Imidazotriaines and imidazopyrimidines as kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-03-01 | — | — | US | disclosed |
| US-20200317680-A1 | Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors | INCYTE HOLDINGS CORPORATION | 2020-10-08 | — | — | US | disclosed |
| US-10738052-B2 | Imidazotriaines and imidazopyrimidines as kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2020-08-11 | — | — | US | disclosed |
| EP-3443958-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | Incyte Holdings Corporation (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20180282340-A1 | Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors | INCYTE CORPORATION | 2018-10-04 | — | — | US | disclosed |
| EP-3034075-B1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE HOLDINGS CORP (US) | 2018-07-25 | — | — | EP | disclosed |
| US-9944645-B2 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | INCYTE CORPORATION (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160326178-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION | 2016-11-10 | — | — | US | disclosed |
| EP-3034075-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | Incyte Holdings Corporation (US) | 2016-06-22 | — | — | EP | disclosed |
| EP-2497470-B1 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | INCYTE CORP (US) | 2015-10-28 | — | — | EP | disclosed |
| US-8461330-B2 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | INCYTE CORPORATION (US) | 2013-06-11 | — | — | US | disclosed |
| CN-101641093-B | Imidazotriazines and imidazopyrimidines as kinase inhibitors | INCYTE CORP | 2013-05-29 | — | — | CN | disclosed |
| EP-2099447-B1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORP (US) | 2012-11-07 | — | — | EP | disclosed |
| EP-2497470-A1 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | Incyte Corporation (US) | 2012-09-12 | — | — | EP | disclosed |
| CN-101641093-A | Imidazotriazines and imidazopyrimidines as kinase inhibitors | INCYTE CORP US | 2010-02-03 | — | — | CN | disclosed |
| EP-2099447-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | Incyte Corporation (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008064157-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326178-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | ERBB2, MERTK, ABL1 | PDK2 1015/4885FFAR1 2624/4885FEN1 2121/4885 |
| US-20230002392-A1 | Imidazotriazines and Imidazopyrimidines as Kinase Inhibitors | ERBB2, MERTK, ABL1 | PDK2 1015/4885FFAR1 2624/4885FEN1 2121/4885 |
| US-20180282340-A1 | Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors | MET, RET, ERBB2 | PDK2 960/4885FFAR1 2456/4885FEN1 1820/4885 |
| US-20200317680-A1 | Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors | MET, RET, ERBB2 | PDK2 960/4885FFAR1 2456/4885FEN1 1820/4885 |
| US-11261191-B2 | Imidazotriaines and imidazopyrimidines as kinase inhibitors | MET, RET, ERBB2 | PDK2 960/4885FFAR1 2456/4885FEN1 1820/4885 |
| US-10738052-B2 | Imidazotriaines and imidazopyrimidines as kinase inhibitors | MET, RET, ERBB2 | PDK2 960/4885FFAR1 2456/4885FEN1 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.